The expansion of Pharmacy First represents an important step forward for community pharmacy and, more importantly, for patients.
It provides an opportunity to make better use of the skills and clinical expertise that already exist within community pharmacies, while improving access to care at a time when pressure on general practice and urgent care services remains high.
For pharmacy businesses, the new pathways have the potential to increase the clinical role of the community pharmacy and strengthen its position as a first point of contact for patients.
But the opportunity needs to be considered alongside the practical realities of delivering a clinically led service, including workforce capacity, consultation space, training, governance and the ability to manage demand safely and effectively.
For prescribing pharmacists in particular, Pharmacy First is an opportunity to demonstrate the value of their clinical skills.
Pharmacists are increasingly moving beyond the traditional dispensing role and becoming clinicians who can assess patients, make clinical decisions and prescribe where appropriate.
The new pathways can help accelerate that transformation and give pharmacists greater professional recognition as independent healthcare professionals.
This is an opportunity to redefine how patients access primary care and to demonstrate the contribution that pharmacists can make as clinicians.
The choice of clinical areas is also important. The pathways need to cover conditions that are appropriate for assessment and treatment within community pharmacy, while providing clear boundaries around when patients should be referred onwards.
If implemented effectively, this could provide a much more convenient experience for patients and reduce unnecessary pressure elsewhere in the NHS.
However, funding will be critical to the success of the programme. Community pharmacy contractors will need to be confident that the remuneration reflects not only the consultation itself but also the wider costs of delivering a safe and sustainable clinical service.
Pharmacy businesses are already operating in a challenging financial environment, so participation cannot simply be viewed as an additional source of activity. The economics need to work alongside the clinical case. the funding is from same envelope and nothing extra.
The level of contractor uptake will therefore depend on a number of factors, including the final funding arrangements, local demand, workforce availability and how straightforward the service is to deliver.
I would expect there to be some interest across the sector, but participation is likely to vary depending on the individual circumstances of each pharmacy.
Ultimately, Pharmacy First should be seen as more than simply another service for community pharmacy to deliver.
It is an opportunity to redefine how patients access primary care and to demonstrate the contribution that pharmacists can make as clinicians.
Some of the new Pharmacy First clinical pathways could be easily done via PGD, so it seems that the IP requirement is a tick box or PR exercise to fulfil the pledge of using IP.
There is a possibility that some IPs and non-IPs will choose the PGD route as private service, bringing in a two-tier system as with dentistry, which would be detrimental to those in deprived areas.
We cannot ignore another key issue, that we don’t have enough IPs to provide nationwide NHS service.
If the pathways are properly funded, supported and integrated with the wider NHS, Pharmacy First could become an important part of delivering faster primary care health services to patients and reducing GP appointment waiting times..
The ambition should be to create a service that works for patients, pharmacists, pharmacy businesses and the NHS as a whole.
